Media headlines about Iqvia (NYSE:IQV) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iqvia earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.9525593002802 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Head to Head Contrast: Iqvia (IQV) & The Competition (americanbankingnews.com)
- Iqvia (IQV) versus Its Peers Financial Survey (americanbankingnews.com)
- Are you searching Analysts Rated Stock: IQVIA Holdings Inc. (IQV) – Wall Street Morning (wallstreetmorning.com)
- Market Trends Toward New Normal in Ashland Global, BioCryst Pharmaceuticals, PICO, Chicago Rivet & Machine, Mercury General, and IQVIA Holdings — Emerging Consolidated Expectations, Analyst Ratings (finance.yahoo.com)
- ETFs with exposure to IQVIA Holdings, Inc. : December 19, 2017 (finance.yahoo.com)
Iqvia (NYSE IQV) traded down $0.18 during mid-day trading on Thursday, reaching $100.14. The company’s stock had a trading volume of 1,288,718 shares, compared to its average volume of 1,490,293. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia has a 52 week low of $74.73 and a 52 week high of $110.67. The stock has a market cap of $21,060.86, a P/E ratio of 23.12, a PEG ratio of 1.61 and a beta of 0.61.
A number of research firms have recently commented on IQV. TheStreet upgraded Iqvia from a “c+” rating to a “b” rating in a report on Wednesday, December 13th. Mitsubishi UFJ Financial Group began coverage on Iqvia in a report on Friday, December 15th. They set a “neutral” rating and a $112.00 target price on the stock. KeyCorp reiterated a “buy” rating and set a $100.00 target price on shares of Iqvia in a report on Sunday, September 24th. Robert W. Baird reiterated a “hold” rating and set a $98.00 target price on shares of Iqvia in a report on Monday, October 9th. Finally, Zacks Investment Research downgraded Iqvia from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Iqvia currently has a consensus rating of “Buy” and a consensus price target of $106.94.
In other news, insider James H. Erlinger III sold 10,000 shares of Iqvia stock in a transaction that occurred on Wednesday, September 27th. The stock was sold at an average price of $94.52, for a total value of $945,200.00. Following the completion of the transaction, the insider now owns 27,340 shares in the company, valued at approximately $2,584,176.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of Iqvia stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total value of $764,776,314.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,852,638 shares of company stock worth $903,028,661 over the last 90 days. 6.40% of the stock is owned by company insiders.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.